94 results
D
ELDN
Eledon Pharmaceuticals Inc
22 May 24
Indefinite amount in equity / options / securities to be acquired, sold $50.00 mm, 24 investors
7:36pm
are "covered securities" for purposes
of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D
8-K
EX-10.2
ELDN
Eledon Pharmaceuticals Inc
7 May 24
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
7:15am
)Independent Nature of Holders’ Obligations and Rights. The obligations of each Holder hereunder are several and not joint with the obligations of any
8-K
EX-10.1
ELDN
Eledon Pharmaceuticals Inc
7 May 24
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
7:15am
to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted … or such enforcement or setoff had not occurred.
5.17Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under
8-K
EX-10.1
v3hcm9515n
20 Sep 23
Departure of Directors or Certain Officers
7:09pm
D
f4xve0x2t grc9x
22 May 23
Indefinite amount in equity / options / securities to be acquired, sold $35.00 mm, 38 investors
1:26pm
8-K
EX-10.1
r8rvg6ra3d
1 May 23
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
7:27am
8-K
EX-10.2
c03t6yvqm0q5 lrs
1 May 23
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
7:27am